Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 566
- 试验地点
- 1
- 主要终点
- Cumulative rate of culture-confirmed or clinically diagnosed TB disease in participants
研究概览
简要总结
Tuberculosis (TB) remains the most important infectious disease in the world. Preventive treatment plays an important role in successful control of TB. For preventive therapy, the three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) are now recommended by WHO for its non-inferiority, safety and convenience compared with 6~9 months regimen of daily isoniazid monotherapy or 3~4 months daily rifampicin monotherapy. And the treatment completion rate is higher compared with daily regimen. However, relevant study is lacking in China where the TB burden is high with the incidence rate of 70/100, 000. And the provision of chemoprophylaxis is not recommended in China currently.
Silicosis is a high risk factor of Mycobacterium tuberculosis infection. This is an open-label, randomized, Phase III clinical trial to evaluate the effectiveness and tolerability of the 3RPT/INH to prevent tuberculosis (TB) compared with those who do not receive preventive treatment among silicotic patients.
详细描述
Tuberculosis (TB) remains the most important infectious disease in the world. Preventive treatment plays an important role in successful control of TB. For preventive therapy, the three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) are now recommended by WHO for its non-inferiority, safety and convenience compared with 6~9 months regimen of daily isoniazid monotherapy or 3~4 months daily rifampicin monotherapy. And the treatment completion rate is higher compared with daily regimen. However, relevant study is lacking in China where the TB burden is high with the incidence rate of 70/100, 000.
Silicosis is a high risk factor of Mycobacterium tuberculosis infection. This is an open-label, randomized, Phase III clinical trial to evaluate the effectiveness and tolerability of the 3RPT/INH to prevent tuberculosis (TB) among silicotic patients.
The PRIMARY objective of this open-label, randomized, Phase III clinical trial is to evaluate the effectiveness of the 3RPT/INH to prevent TB compared with those who do not receive preventive treatment among eligible silicotic patients.
The SECONDARY objective:
Describe the safety profile of 3RPT/INH in China (the rates of drug discontinuation for any reason and due to adverse drug reactions associated with 3RPT/INH, the rates of any grade 3, 4, or 5 drug toxicity associated with 3RPT/INH) Describe the treatment completion rates of 3RPT/INH. Describe patterns of antibiotic resistance of M. tuberculosis isolates in patients who develop TB despite preventive treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Individuals with Silica exposure or diagnosed with silicosis;
- •Age between 18 to 65 years;
- •Willing to provide signed informed consent, or parental consent and participant assent.
排除标准
- •Clinical or culture confirmed active TB;
- •A history of treatment for > 14 consecutive days with a rifamycin or > 30 consecutive days with INH during the previous 2 years;
- •A documented history of a completing an adequate course of treatment for active TB or latent TB infection;
- •Allergy to Isoniazid, Rifampin, or Rifapentine;
- •Human immunodeficiency virus (HIV) infection;
- •History of hepatitis B/C infection or liver cirrhosis;
- •Serum Aspartic transaminase (AST) or alanine transaminase (ALT) > 2x upper limit of normal or total bilirubin >2.5 mg/dL;
- •Receiving immunosuppressants or biological agents;
- •Life expectancy <3 years;
- •Mental disorder;
- •Participated in other clinical trials in recent three months;
- •Other conditions that investigates consider not suitable for participate.
研究组 & 干预措施
Weekly Isoniazid / Rifapentine
Weekly INH / RRT given by DOT
干预措施: Weekly INH / RRT given by DOT (Drug)
结局指标
主要结局
Cumulative rate of culture-confirmed or clinically diagnosed TB disease in participants
时间窗: 3 years
次要结局
- Percentage of participants with drug discontinuation for any reason and due to adverse drug reactions associated with 3RPT/INH(up to 30 days after the last dose of study drug)
- Percentage of patients with Grade 3 or 4 drug toxicities and deaths associated with 3RPT/INH(up to 30 days after the last dose of study drug)
- Percentage of participants who complete the treatment regimen(Enrollment up to Month 3 (3RPT/INH))
- The proportion of rifampicin and/or isoniazid resistance of M. tuberculosis isolates in patients who develop TB in preventive treatment group.(3 years)
- Measure the quantitative and qualitative changes of the results of QuantiFERON Gold In-Tube before and after preventive treatment.(Enrollment up to 3 months after preventive treatment)
研究者
Wen-hong Zhang
Director of Division of Infectious Diseases
Huashan Hospital